611,013 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 611,013 shares of the company’s stock, valued at approximately $7,399,000. Artisan Partners Limited Partnership owned approximately 0.89% of Replimune Group at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares in the last quarter. Geode Capital Management LLC raised its stake in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the last quarter. Barclays PLC boosted its holdings in Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after acquiring an additional 98,791 shares in the last quarter. State Street Corp grew its stake in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its stake in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after acquiring an additional 1,000,000 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright upped their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets boosted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $19.43.

Replimune Group Stock Down 0.6 %

REPL opened at $10.39 on Friday. The stock has a market capitalization of $800.19 million, a price-to-earnings ratio of -3.38 and a beta of 1.30. The firm has a 50 day moving average price of $12.67 and a 200-day moving average price of $12.14. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Equities research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.